(Q34590315)

3 August 2017

1 reference

title

The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene (English)

1 reference

3 August 2017

1 reference

1 reference

Wen-Ling Lee

1

1 reference

3 August 2017

Ming-Huei Cheng

series ordinal

2

1 reference

3 August 2017

Hsiang-Tai Chao

series ordinal

3

1 reference

3 August 2017

Peng-Hui Wang

series ordinal

4

1 reference

3 August 2017

1 March 2008

1 reference

Taiwanese Journal of Obstetrics & Gynecology

3 August 2017

1 reference

3 August 2017

47

1 reference

3 August 2017

1

1 reference

3 August 2017

24-31

1 reference

Estrogen carcinogenesis in breast cancer

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Breast cancer and hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Standard and low-dose hormone therapy for postmenopausal women--focus on the breast

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Effects of tibolone on the breast of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Canadian Consensus Conference on osteoporosis, 2006 update.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Breast cancer risk with postmenopausal hormonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Estrogen receptor null mice: what have we learned and where will they lead us?

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Oestrogen receptors - an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

The Molecular Pharmacology of SERMs

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Selective estrogen receptor modulation: concept and consequences in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Potential role of tamoxifen in prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Tamoxifen: five versus ten years--is the end in sight?

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Risk-benefit profiles of raloxifene for women

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Tamoxifen therapy for breast cancer and endometrial cancer risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Secretory endometrial adenocarcinoma in a tamoxifen user with breast cancer after menopause

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

A reconsideration of tamoxifen use for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

SERMs for the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Prevention of hormone-related cancers: breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Raloxifene and the prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1028-4559%2808%2960051-0

7 January 2021

10.1016/S1028-4559(08)60051-0

Identifiers

DOI

1 reference

3 August 2017

1 reference